Covid-19 vaccine: Zydus Cadila to begin phase II trials of ZyCoV-D today
New Delhi: Drug firm Zydus Cadila on Wednesday said the phase I clinical trial of its Covid-19 vaccine candidate, ZyCoV-D, has been completed and it will commence phase II clinical trials from August 6.
"ZyCoV-D was found to be safe and well-tolerated in phase I clinical trial. The company will now commence phase II clinical trials from the 6th of August, 2020.
"The company reports that the doses of the vaccine administered to healthy volunteers in phase I clinical trial, which began on July 15, 2020, has been well-tolerated," Cadila Healthcare, the listed entity of the group, said in a regulatory filing.
Zydus Cadila Chairman Pankaj R Patel said the phase I dosing to establish the safety of ZyCoV-D is an important milestone.
"All the subjects in phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post-dosing for safety and for 7 days thereafter and the vaccine was found to be very safe. We now begin the phase II clinical trials and look forward to evaluating the safety and immunogenicity of the vaccine in a larger population, he added.
Last month, Zydus had received approval from domestic authorities to start human trials for its Covid-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.